News Conference News TCT 2015 Valve-in-Valve TAVR Benefits Patients with Failing Surgical Bioprosthetic Valves Todd Neale October 15, 2015
News Conference News TCT 2015 Initial Surgical AVR Improves Long-term Outcomes in Asymptomatic Patients With Severe AS October 15, 2015
News Industry News Thrombus Aspiration During PCI Shows No Benefit To Standard PCI In Stemi Patients Presenting Late After Symptom Onset October 13, 2015
News Industry News Medtronic CoreValve® System Shows Positive Clinical Outcomes in New Patient Populations October 13, 2015
News Conference News TCT 2015 EXPLORE: Treating CTOs After STEMI Does Not Improve LV Function Todd Neale October 13, 2015
News Conference News TCT 2015 Current State of Percutaneous Valve Therapies for Use in Congestive HF Explored October 13, 2015
News Conference News TCT 2015 V-Wave Device Offers Functional, Hemodynamic Gains for Patients With Systolic HF October 11, 2015
News Conference News TCT 2015 Cardioband Shows Benefits for Secondary Mitral Regurgitation October 11, 2015
News Industry News Extended Follow-Up Of ANTHEM-HF Patients Shows That Benefits Of Autonomic Regulation Therapy Are Maintained After 12 Months September 28, 2015
News Conference News ESC 2015 Danish Registry Study Shows Potential of Stroke Risk Score in Heart Failure Patients L.A. McKeown August 31, 2015
News Industry News Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure August 31, 2015
News Conference News ESC 2015 Failed Trial PRomPTs Questions About Role of Peri-Infarct Pacing for Remodeling of Large MIs L.A. McKeown August 30, 2015
News Daily News High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease Todd Neale August 17, 2015
News Daily News COURAGE Substudy: PCI Adds No Overall Benefit to OMT Alone in Either Women or Men L.A. McKeown August 03, 2015
News Daily News FDA Approves Heart Failure Drug That Comes With Survival Benefit Todd Neale July 13, 2015
News Industry News Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan) July 07, 2015